Relmada Therapeutics (RLMD) Receivables (2021 - 2022)

Relmada Therapeutics' (RLMD) quarterly Receivables came in at $1.0 million in Q4 2022, down 71.6% on a QoQ basis from $3.6 million in Q1 2022.

Relmada Therapeutics (RLMD) Receivables (2021 - 2022) Analysis & Trends

Relmada Therapeutics (RLMD) has 2 years of Receivables data on file, last reported at $1.0 million in Q4 2022.

On a quarterly basis, Receivables changed N/A year-over-year to $1.0 million in Q4 2022; TTM through Dec 2022 was $1.0 million, a N/A change from a year earlier, with the FY2022 full-year figure at $1.0 million, changed N/A from the prior year.
Receivables for Q4 2022 stood at $1.0 million, down from $3.6 million in the prior quarter.
Over the last five years, Receivables for RLMD reached as high as $3.6 million in Q1 2022 and fell as low as $1.0 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	4.97 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	938.02 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	1.13 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	2.00 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	5.73 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.93 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Relmada Therapeutics	205.29 Mn	205.29 Mn	-	-

Download Data